AnaptysBio, Inc. (ANAB) financial statements (2020 and earlier)

Company profile

Business Address 10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments374427248
Cash and cash equivalents17111481
Short-term investments203313167
Other undisclosed current assets474
Total current assets:378434253
Noncurrent Assets
Property, plant and equipment211
Long-term investments and receivables547376
Long-term investments547376
Deposits noncurrent assets  0
Restricted cash and investments000
Other noncurrent assets10 
Total noncurrent assets:577577
TOTAL ASSETS:435509329
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities27147
Accounts payable1652
Accrued liabilities1195
Debt187
Other liabilities100
Total current liabilities:302214
Noncurrent Liabilities
Long-term debt and lease obligation 18
Long-term debt, excluding current maturities 18
Liabilities, other than long-term debt100
Accounts payable and accrued liabilities 00
Other liabilities1  
Total noncurrent liabilities:118
Total liabilities:302322
Stockholders' equity
Stockholders' equity attributable to parent405486308
Common stock000
Additional paid in capital649633393
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(244)(147)(85)
Total stockholders' equity:405486308
TOTAL LIABILITIES AND EQUITY:435509329

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenue, net10
Gross profit:8510
Operating expenses(115)(72)(39)
Operating loss:(107)(67)(29)
Nonoperating income (expense)105(1)
Investment income, nonoperating  2
Other nonoperating income (expense)0(0)0
Interest and debt expense(1)(2)(2)
Loss from continuing operations before equity method investments, income taxes:(99)(64)(32)
Other undisclosed income from continuing operations before income taxes122
Loss from continuing operations before income taxes:(97)(62)(30)
Income tax benefit00 
Net loss available to common stockholders, diluted:(97)(62)(30)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(97)(62)(30)
Other comprehensive income (loss) 0(0)
Comprehensive loss:(97)(61)(30)
Other undisclosed comprehensive income, net of tax, attributable to parent1  
Comprehensive loss, net of tax, attributable to parent:(97)(61)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: